Cloud-Clone pushes full-link cloning platform for biomedicine

Cloud-Clone Corp. says it has built an end-to-end cloning platform spanning gene manipulation through finished reagents, aiming to speed research and product development for biomedicine customers. The company is also pointing to a broad product catalog, including recombinant proteins, antibodies, ELISA kits and primary cells, as it targets global research and industrial markets.

Why it matters: - Cloud-Clone is positioning full-link cloning as a way to shorten the path from basic gene work to finished research reagents. - The company says the model could reduce workflow fragmentation for biopharmaceutical, academic and clinical research users. - Cloud-Clone also says the platform supports precision medicine, drug discovery, agricultural breeding and biodiversity research.

What happened: - Cloud-Clone Corp. announced an all-in-one cloning solutions platform built around molecular, cell and organism cloning. - The company said the platform combines gene cloning, protein cloning, antibody cloning and related technologies into one resource system. - The release also highlighted the company’s global research focus and its push to serve institutions and biopharmaceutical enterprises worldwide.

The details: - Cloud-Clone says its full-spectrum cloning system covers end-to-end R&D from gene manipulation to finished product manufacturing. - The company says it has developed more than 18,000 recombinant protein products, including Interleukin-4 and Calcitonin. - Cloud-Clone says its antibody portfolio includes monoclonal, polyclonal and recombinant antibodies, including a Creatine Kinase antibody. - The company says its ELISA kits have been used as experimental tools in research published in journals including Nature Medicine and Nature Communications since early 2026. - Cloud-Clone says it provides primary cell products from human, rat, mouse, rabbit, canine and feline sources. - The company lists feline bone marrow mesenchymal stem cells, canine bone marrow mesenchymal stem cells and rabbit visceral preadipocytes among its cell offerings. - Cloud-Clone says its product catalog includes more than 70,000 cloning-related products. - The company says its internal platforms support in-house antigen and antibody development and production. - Cloud-Clone says it provides CRO services, proteins, antibodies, ELISA kits, primary cells and multiplex cytokine assay kits. - More information is available on Cloud-Clone's website. - The company also listed social channels on LinkedIn, Instagram, TikTok, LinkedIn profile, Instagram profile, TikTok profile and X.

Between the lines: - The announcement is as much a platform statement as a product release, with Cloud-Clone framing its business around an integrated workflow instead of individual reagents. - The company is leaning on breadth of catalog and vertical integration as its main competitive claims. - The release also uses the history of cloning technology to argue that Cloud-Clone’s portfolio sits inside a larger research and translational medicine trend.

What's next: - Cloud-Clone says it will keep integrating cloning resources, optimizing workflows and lowering barriers to academic and industrial use. - The company expects its technology to support future work in science, medicine, sustainable agriculture and conservation. - The release points to continued expansion of application areas as the company develops its platform further.

The bottom line: - Cloud-Clone is betting that one integrated cloning stack can be more useful than separate tools sold one by one.